Gagnon Securities LLC cut its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.2% during the second quarter, Holdings Channel reports. The firm owned 1,968 shares of the biopharmaceutical company’s stock after selling 4 shares during the period. Gagnon Securities LLC’s holdings in Celgene Corporation were worth $256,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. CHURCHILL MANAGEMENT Corp increased its position in Celgene Corporation by 95.1% in the first quarter. CHURCHILL MANAGEMENT Corp now owns 41,196 shares of the biopharmaceutical company’s stock valued at $5,126,000 after buying an additional 20,077 shares in the last quarter. Gibraltar Capital Management Inc. increased its position in Celgene Corporation by 0.9% in the first quarter. Gibraltar Capital Management Inc. now owns 30,206 shares of the biopharmaceutical company’s stock valued at $3,759,000 after buying an additional 271 shares in the last quarter. Hills Bank & Trust Co. increased its position in Celgene Corporation by 2.1% in the first quarter. Hills Bank & Trust Co. now owns 10,763 shares of the biopharmaceutical company’s stock valued at $1,340,000 after buying an additional 218 shares in the last quarter. Boltwood Capital Management increased its position in Celgene Corporation by 13.9% in the first quarter. Boltwood Capital Management now owns 6,770 shares of the biopharmaceutical company’s stock valued at $842,000 after buying an additional 825 shares in the last quarter. Finally, Trust Co increased its position in Celgene Corporation by 2.8% in the fourth quarter. Trust Co now owns 17,135 shares of the biopharmaceutical company’s stock valued at $1,983,000 after buying an additional 465 shares in the last quarter. 78.41% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Celgene Corporation (CELG) traded up 0.18% on Friday, hitting $130.61. 2,735,623 shares of the stock were exchanged. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company has a market cap of $102.18 billion, a P/E ratio of 40.45 and a beta of 1.89. The firm’s 50-day moving average is $134.14 and its 200-day moving average is $124.30.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the business earned $1.44 earnings per share. The firm’s revenue was up 18.7% compared to the same quarter last year. On average, equities analysts forecast that Celgene Corporation will post $7.32 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Celgene Corporation (NASDAQ:CELG) Position Cut by Gagnon Securities LLC” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/celgene-corporation-nasdaqcelg-position-cut-by-gagnon-securities-llc.html.

CELG has been the subject of several research analyst reports. BTIG Research restated a “buy” rating and issued a $138.00 price objective on shares of Celgene Corporation in a research note on Wednesday, May 24th. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and upped their price objective for the company from $96.93 to $160.00 in a research note on Monday, July 31st. Jefferies Group LLC restated a “buy” rating and issued a $160.00 price objective on shares of Celgene Corporation in a research note on Tuesday, July 11th. Zacks Investment Research downgraded shares of Celgene Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Finally, Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the stock. Celgene Corporation presently has a consensus rating of “Buy” and a consensus price target of $147.00.

In other news, insider Robert J. Hugin sold 175,970 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the sale, the insider now owns 1,033,909 shares in the company, valued at $138,688,553.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rupert Vessey sold 4,785 shares of the business’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total transaction of $575,061.30. Following the sale, the insider now owns 4,004 shares in the company, valued at approximately $481,200.72. The disclosure for this sale can be found here. Insiders have sold 235,255 shares of company stock worth $31,377,042 in the last 90 days. 0.95% of the stock is owned by company insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.